Takeda: Phase 3 study closed enrollment, 601 enrolled (Psoriatic Arthritis)
Takeda: Phase 3 study closed enrollment, 601 enrolled (Psoriatic Arthritis). Its enrollment of 601 is top-decile (91st percentile of 8,879 records). Dated 21 days ago, it is in the active follow-up window. Score 75/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 601 · 91th percentile of 8,879 ClinicalTrialStartPulse records · 7.5x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Takeda |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines |
| NCT ID | NCT06671496 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Psoriatic Arthritis |
| Intervention types | drug |
| Target enrollment | 601 |
| Site countries | United States, Argentina, Australia, Brazil, Canada, China, France, Germany, Japan, Poland, Spain, United Kingdom |
| Posted | 2024-11-04 |
| Planned start | 2025-03-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-14 |
| Last update posted | 2026-10-14 |
| enrollment percentile | 91th of 8,879 (median 80, 7.5x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Takeda
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Takeda + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-14
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Takeda and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- Takeda's enrollment: 91st percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 601 participants planned.
What is the ClinicalTrialStartPulse record for Takeda?
Takeda's Phase 3 study (NCT06671496) in Psoriatic Arthritis, first posted 2024-11-04: enrollment closed (active, not recruiting) (2026-10-14), in an update posted 2026-10-14.
How does Takeda compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 601 is 7.5x the median of 80 across 8,879 records. It is 21 days old, still within a typical 45-day follow-up window. Its Score of 75/100 puts it among the stronger signals in this feed.
Takeda vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Takeda | US | 601 | 91st | 2026-10-14 |
| Genmab | US | 600 | 91st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 539 | 90th | 2026-11-03 |
| Janssen Research & Development, LLC | US | 743 | 92nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor Takeda and peer phase 3 records
Get new ClinicalTrialStartPulse records like Takeda by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.